ESTIMATING SCENARIOS FOR SURVIVAL TIME IN PATIENTS WITH METASTATIC MELANOMA STARTING TARGETED THERAPIES AND IMMUNOTHERAPY

被引：0
|
作者：
Vasista, A. [1 ,2 ]
Stockler, M. R. [1 ]
Carlino, M. S. [2 ,3 ]
Kiely, B. E. [1 ]
机构：
[1] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW, Australia
[2] Univ Sydney, Westmead Hosp, Sydney, NSW, Australia
[3] Melanoma Inst Australia, Sydney, NSW, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：70 / 70
页数：1
相关论文
共 50 条
  • [21] Estimating scenarios for survival time in men starting systemic therapies for castration-resistant prostate cancer: A systematic review of randomised trials
    West, T. A.
    Kiely, B. E.
    Stockler, M. R.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (11) : 1916 - 1924
  • [22] Melanoma-associated retinopathy after starting immunotherapy for metastatic cutaneous melanoma
    Mariantonia Ferrara
    Wendy Adams
    Ajay Kotagiri
    Eye, 2022, 36 : 2361 - 2362
  • [23] Melanoma-associated retinopathy after starting immunotherapy for metastatic cutaneous melanoma
    Ferrara, Mariantonia
    Adams, Wendy
    Kotagiri, Ajay
    EYE, 2022, 36 (12) : 2361 - 2362
  • [24] Prognostic factors for response and survival in patients with metastatic melanoma receiving immunotherapy
    Keilholz, U
    Scheibenbogen, C
    Sommer, M
    Pritsch, M
    Geuke, AM
    MELANOMA RESEARCH, 1996, 6 (02) : 173 - 178
  • [25] Targeted Therapies in Metastatic Melanoma: Toward a Clinical Breakthrough?
    Julia, Fanny
    Thomas, Luc
    Dumontet, Charles
    Dalle, Stephane
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2010, 10 (09) : 661 - 665
  • [26] Oligoprogression After Immunotherapy and Targeted Therapy in Metastatic Melanoma
    Sobrevilla-Moreno, Nora
    Rivera-Sanchez, Daniel
    Garcia-Ortega, Dorian Y.
    Lopez-Macias, Diego
    Garcilazo-Reyes, Alexandra
    Alvarez-Avitia, Miguel A.
    ONCOLOGY-NEW YORK, 2021, 35 (09): : 562 - 566
  • [27] Targeted therapy and immunotherapy: Emerging biomarkers in metastatic melanoma
    LoRusso, Patricia M.
    Schalper, Kurt
    Sosman, Jeffrey
    PIGMENT CELL & MELANOMA RESEARCH, 2020, 33 (03) : 390 - 402
  • [28] Beyond median overall survival: Estimating multiple survival scenarios in patients with metastatic esophagogastric cancer
    Pape, Marieke
    Kuijper, Steven
    Vissers, Pauline A. J.
    Creemers, Geert-Jan
    Van Laarhoven, Hanneke W. M.
    Verhoeven, Rob
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [29] Combination of immunotherapy and other targeted therapies in advanced cutaneous melanoma
    Marconcini, Riccardo
    Pezzicoli, Gaetano
    Stucci, Luigia Stefania
    Sergi, Maria Chiara
    Lospalluti, Lucia
    Porta, Camillo
    Tucci, Marco
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (03)
  • [30] NEW SYSTEMIC THERAPIES FOR METASTATIC MELANOMA - MAPK INHIBITORS AND IMMUNOTHERAPY
    Menzies, Alexander M.
    CANCER FORUM, 2012, 36 (03) : 156 - 161
12345